This disclosure provides methods for treating a hepatocellular carcinoma(e.g., unresectableHCC) with lenvatinib or a pharmaceutically acceptable salt thereof. Alsoencompassed by thedisclosure are dosage regimens described herein of lenvatinib or apharmaceutically acceptablesalt thereof for use in treating hepatocellular carcinoma (e.g., unresectablehepatocellularcarcinoma) according to any of the methods described herein. Particularlyuseful dosages anddose modifications upon the occurrence of an adverse event or events are alsodisclosed.
